PYXS Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$6.75median target· current $2.36 (+186.0%)9 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.300.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$149.5MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 4.80
- P/S (TTM)
- 10.79
- EV/EBITDA
- 1.09
Profitability & growth
- ROE (TTM)
- -121.7%
- Operating margin
- -600.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 1.31
Last earnings
May 14, 2026 · Estimate $-0.34 · Reported $-0.37
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Pyxis Oncology Inc
Company profilePyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 321 HARRISON AVENUE, BOSTON, MA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$149.5M
Shares outstanding$63.4M
52W high$5.55
52W low$0.97
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent